Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

Roche To Commence Phase III Trials With Innovative Treatment Designed To Lower Cardiovascular Risk In Diabetes Patients With Recent Heart Attack
Roche announced it will start Phase III clinical investigations for aleglitazar, its innovative PPAR co-agonist R1439 which is uniquely designed to reduce cardiovascular morbidity and mortality in high risk patients with type 2 diabetes. This decision is supported by data from the Phase II SYNCHRONY study published today in The Lancet(1) and announced at the American Diabetes Association meeting in New Orleans. The Phase III program is anticipated to start in the second half of 2009.
generic viagra online
Seattle Genetics Initiates Brentuximab Vedotin (SGN-35) Retreatment Clinical Trial
Seattle Genetics, Inc. (Nasdaq: SGEN) announced that it has initiated a phase II clinical trial of brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC), for the retreatment of patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL). This trial is designed to evaluate tolerability and activity when retreating patients who relapse after previously achieving an objective response to brentuximab vedotin. Drugshop to buy zoloft online and other pills.
News of the day
First Human Receives Cardiac Stem Cells In Clinical Trial To Heal Damage Caused By Heart Attacks
Doctors at the Cedars-Sinai Heart Institute announced today the completion of the first procedure in which a patient"s own heart tissue was used to grow specialized heart stem cells that were then injected back into the patient"s heart in an effort to repair and re-grow healthy muscle in a heart that had been injured by a heart attack. The minimally-invasive procedure was completed on the first patient on Friday, June 26.
Health Insurance

Association of American Medical Colleges Praises Nomination Of Francis S. Collins, M.D., Ph.D., To Be New NIH Director

AAMC (Association of American Medical Colleges) President and CEO Darrell G. Kirch, M.D., issued the following statement today on President Obama"s nomination of Francis S. Collins, M.D., Ph.D., to be the new director of the National Institutes of Health (NIH): "The nation"s medical schools and teaching hospitals are very pleased that President Obama"s nominee to be the 16th director of the National Institutes of Health is Dr. Francis Collins. He is an exceptional scientist, administrator, and communicator. Dr. Collins" brilliant leadership of the International Human Genome Sequencing Consortium resulted in the successful completion of the project ahead of schedule and under budget. His skillful direction of this collaborative venture-one of the greatest technical, scientific, and management accomplishments of our lifetime-is just one example of the expertise he will bring to the NIH and its 27 institutes and centers. In addition, Dr. Collins has written eloquently about the potential of medical research to transform how we think about health and health care. America is very fortunate to have a scientist of Dr. Collins" experience, understanding, and vision willing to serve as leader of the world"s foremost biomedical and behavioral research enterprise. The AAMC looks forward to working with Dr. Collins as he leads the NIH forward in this period of tremendous scientific potential and fiscal, administrative, and research challenges." Association of American Medical Colleges


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009